AEZS vs. ATHE, MBRX, GRTX, BFRI, AKTX, ADIL, GHSI, ELAB, MTEM, and LGVN
Should you be buying Aeterna Zentaris stock or one of its competitors? The main competitors of Aeterna Zentaris include Alterity Therapeutics (ATHE), Moleculin Biotech (MBRX), Galera Therapeutics (GRTX), Biofrontera (BFRI), Akari Therapeutics (AKTX), Adial Pharmaceuticals (ADIL), Guardion Health Sciences (GHSI), Elevai Labs (ELAB), Molecular Templates (MTEM), and Longeveron (LGVN). These companies are all part of the "pharmaceutical preparations" industry.
Aeterna Zentaris (NASDAQ:AEZS) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings, media sentiment and community ranking.
Aeterna Zentaris presently has a consensus target price of $15.00, indicating a potential upside of 669.23%. Alterity Therapeutics has a consensus target price of $7.00, indicating a potential upside of 177.78%. Given Aeterna Zentaris' higher possible upside, analysts clearly believe Aeterna Zentaris is more favorable than Alterity Therapeutics.
0.7% of Aeterna Zentaris shares are owned by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are owned by institutional investors. 0.1% of Aeterna Zentaris shares are owned by insiders. Comparatively, 38.8% of Alterity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Alterity Therapeutics has lower revenue, but higher earnings than Aeterna Zentaris.
In the previous week, Aeterna Zentaris had 1 more articles in the media than Alterity Therapeutics. MarketBeat recorded 2 mentions for Aeterna Zentaris and 1 mentions for Alterity Therapeutics. Aeterna Zentaris' average media sentiment score of 0.50 beat Alterity Therapeutics' score of -1.00 indicating that Aeterna Zentaris is being referred to more favorably in the media.
Aeterna Zentaris has a beta of 1.57, meaning that its share price is 57% more volatile than the S&P 500. Comparatively, Alterity Therapeutics has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500.
Alterity Therapeutics has a net margin of 0.00% compared to Aeterna Zentaris' net margin of -368.01%. Alterity Therapeutics' return on equity of 0.00% beat Aeterna Zentaris' return on equity.
Aeterna Zentaris received 416 more outperform votes than Alterity Therapeutics when rated by MarketBeat users. Likewise, 62.54% of users gave Aeterna Zentaris an outperform vote while only 60.00% of users gave Alterity Therapeutics an outperform vote.
Summary
Aeterna Zentaris and Alterity Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.
Get Aeterna Zentaris News Delivered to You Automatically
Sign up to receive the latest news and ratings for AEZS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AEZS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aeterna Zentaris Competitors List
Related Companies and Tools
